These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16416553)

  • 21. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
    Stanton V
    J Natl Cancer Inst; 2012 Aug; 104(16):1265-6; author reply 1266-8. PubMed ID: 22851267
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
    Buzdar AU; Guastalla JP; Nabholtz JM; Cuzick J; ATAC Trialists' Group
    Cancer; 2006 Aug; 107(3):472-80. PubMed ID: 16804925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Buzdar AU; Cuzick J
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1037s-1048s. PubMed ID: 16467122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
    Kelly CM; Pritchard KI
    J Natl Cancer Inst; 2012 Mar; 104(6):427-8. PubMed ID: 22395645
    [No Abstract]   [Full Text] [Related]  

  • 25. Breast-cancer drug letrozole picks up where tamoxifen leaves off. But we don't know who stands to benefit the most from this follow-up approach.
    Runowicz CD
    Health News; 2003 Dec; 9(12):4-5. PubMed ID: 14679962
    [No Abstract]   [Full Text] [Related]  

  • 26. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
    J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
    Okunade G; Green AR; Ying M; Agrawal A; Paish EC; Aleskandrany M; Winterbottom L; Hassell K; Morgan DA; Ellis IO; Cheung KL
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):76-82. PubMed ID: 19515574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of brain metastases from breast cancer that responded to anastrozole monotherapy.
    Ito K; Ito T; Okada T; Watanabe T; Gomi K; Kanai T; Mochizuki Y; Amano J
    Breast J; 2009; 15(4):435-7. PubMed ID: 19470131
    [No Abstract]   [Full Text] [Related]  

  • 31. Breast cancer (metastatic).
    Johnston S; Stebbing J
    Clin Evid; 2003 Dec; (10):1975-2002. PubMed ID: 15555190
    [No Abstract]   [Full Text] [Related]  

  • 32. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Costa SD; Kaufmann M
    J Clin Oncol; 2001 May; 19(9):2580; author reply 2580-2. PubMed ID: 11331346
    [No Abstract]   [Full Text] [Related]  

  • 33. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Tonkin K
    J Clin Oncol; 2001 May; 19(9):2579-80; author reply 2580-2. PubMed ID: 11331344
    [No Abstract]   [Full Text] [Related]  

  • 34. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Bagley CM; Rowbotham RK
    J Clin Oncol; 2001 May; 19(9):2578-9; author reply 2580-2. PubMed ID: 11331342
    [No Abstract]   [Full Text] [Related]  

  • 35. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Copur MS; Ledakis P; Bolton M; Norvell M; Muhvic J
    J Clin Oncol; 2001 May; 19(9):2578; author reply 2580-2. PubMed ID: 11331343
    [No Abstract]   [Full Text] [Related]  

  • 36. Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
    Boccardo F
    Nat Clin Pract Oncol; 2008 Feb; 5(2):76-7. PubMed ID: 17998944
    [No Abstract]   [Full Text] [Related]  

  • 37. Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Ingle JN
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1031s-1036s. PubMed ID: 16467121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Kahán Z
    Magy Onkol; 2008 Jun; 52(2):225-6. PubMed ID: 18640899
    [No Abstract]   [Full Text] [Related]  

  • 39. Breast cancer (metastatic).
    Stebbing J; Crane J; Gaya A
    Clin Evid; 2006 Jun; (15):2331-59. PubMed ID: 16973089
    [No Abstract]   [Full Text] [Related]  

  • 40. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.